Market News AIOpen the app

H.C. Wainwright cut its price target for Celldex Therapeutics from $64.00 to $58.00 but still rates it a 'Buy.

OpinionRead the original at moomoo.com
Neutral

H.C. Wainwright lowered its share-price target from $64 to $58 but kept its Buy rating.

CLDX · Celldex Therapeutics, Inc.

AI read · Neutral

The AI's read

A lower share-price estimate points to less optimism, but the firm still rates the shares Buy. The story gives no new information about Celldex's research or business, so it does not change the company outlook.

Get alerts for CLDX

Follow Celldex Therapeutics, Inc. (CLDX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CLDX
Free on the App Store and Google Play, or on the web.